A potential game-changing drug for use in the treatment of a common form of vision loss took a step closer to the FDA in October when Ophthotech (ISEE) announced its second phase 3 trial of Fovista for wet age-related macular edema was now fully enrolled.
Investors cheered the news, sending shares up sharply last month, but can Ophthotech's shares continue to climb? In the following slideshow, I discuss Ophthotech's potential, including why a major deal with Novartis (NVS -1.54%) makes this company an intriguing investment for risk-tolerant investors.
Why Ophthotech Corporation Soared In October from The Motley Fool.
